［1］Schultz DC.Identification of two candidate tumor suppressor genes on chromosome 17p13.3［J］.Cancer Res，1996，56(9)：1997-2002.
［2］Phillips NJ，Zeigler MR，Deaven LL.A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3［J］.Cancer Lett，1996，102(1-2)：85-90.
［3］Phillips NJ.Allelic deletion on chromosome 17p13.3 in early ovarian cancer［J］.Cancer Res，1996，56(3)：606-611.
［4］Emi M.Allelic loss at 1p34，13q12，17p13.3，and 17q21.1 correlates with poor postoperative prognosis in breast cancer［J］.Genes Chromosomes Cancer，1999，26(2)：134-141.
［5］Voeghtly LM.Molecular alterations associated with breast cancer mortality［J］.PLoS One，2012，7(10)：e46814.
［6］Kersemaekers AM.Loss of heterozygosity for defined regions on chromosomes 3，11 and 17 in carcinomas of the uterine cervix［J］.Br J Cancer，1998，77(2)：192-200.
［7］Tong R，Yang Q，Wang CY,et al.The significance of OVCA1 expression in cervical lesions and correlation with CyclinD1 and p16［J］.Modern Oncology，2016，24(8)：1264-1268.［佟锐，杨清，王纯雁，等.OVCA1在宫颈病变中表达的意义及与CyclinD1、p16的相关性［J］.现代肿瘤医学，2016，24（8）：1264-1268.］
［8］Sankar M.Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality［J］.Leukemia，1998，12(4)：510-516.
［9］Ninomiya S.Integrated analysis of gene copy number，copy neutral LOH，and microRNA profiles in adult acute lymphoblastic leukemia［J］.Cytogenet Genome Res，2012，136(4)：246-255.
［10］Tsuchiya E.Three new regions on chromosome 17p13.3 distal to p53 with possible tumor suppressor gene involvement in lung cancer［J］.Jpn J Cancer Res，2000，91(6)：589-596.
［11］Shikeeva AA.Allelic imbalance in patients with non-small cell lung cancer［J］.Arkh Patol，2013，75(2)：3-8.
［12］Chattopadhyay P.Loss of heterozygosity of a locus on 17p13.3，independent of p53，is associated with higher grades of astrocytic tumours［J］.Oncogene，1997，15(7)：871-874.
［13］Sarkar C.Role of 17p13.3 chromosomal region in determining p53 protein immunopositivity in human astrocytic tumors［J］.Pathology，2000，32(2)：84-88.
［14］Bruening W.Expression of OVCA1，a candidate tumor suppressor，is reduced in tumors and inhibits growth of ovarian cancer cells［J］.Cancer Res，1999，59(19)：4973-4983.
［15］Chen CM，Behringer RR.Cloning，structure，and expression of the mouse OVCA1 gene［J］.Biochem Biophys Res Commun，2001，286(5)：1019-1026.
［16］Liang M.OVCA1，a candidate gene of the genetic modifier of Tp53，Mop2，affects mouse embryonic lethality［J］.Genes Chromosomes Cancer，2008，47(4)：315-325.
［17］Liu S.Identification of the proteins required for biosynthesis of diphthamide，the target of bacterial ADP-ribosylating toxins on translation elongation factor 2［J］.Mol Cell Biol，2004，24(21)：9487-9497.
［18］Webb TR.Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development［J］.J Cell Sci，2008，121(Pt 19)：3140-3145.
［19］Roy V，Ghani K，Caruso M.A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas exotoxin A and diphtheria toxin［J］.PLoS One，2010，5(12)：e15753.
［20］Abdel-Fattah W.Insights into diphthamide，key diphtheria toxin effector［J］.Toxins (Basel)，2013，5(5)：958-968.
［21］Nobukuni Y，Kohno K，Miyagawa K.Gene trap mutagenesis-based forward genetic approach reveals that the tumor suppressor OVCA1 is a component of the biosynthetic pathway of diphthamide on elongation factor 2［J］.J Biol Chem，2005，280(11)：10572-10577.
［22］Liu S.Diphthamide modification on eukaryotic elongation factor 2 is needed to assure fidelity of mRNA translation and mouse development［J］.Proc Natl Acad Sci USA，2012，109(34)：13817-13822.
［23］Stahl S.Loss of diphthamide pre-activates NF-kappaB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor［J］.Proc Natl Acad Sci USA，2015，112(34)：10732-10737.
［24］Ortiz PA.Translation elongation factor 2 anticodon mimicry domain mutants affect fidelity and diphtheria toxin resistance［J］.J Biol Chem，2006，281(43)：32639-43268.
［25］Su X，Lin Z，Lin H.The biosynthesis and biological function of diphthamide［J］.Crit Rev Biochem Mol Biol，2013，48(6)：515-521.
［26］Arguelles S.Elongation factor 2 diphthamide is critical for translation of two IRES-dependent protein targets，XIAP and FGF2，under oxidative stress conditions［J］.Free Radic Biol Med，2014，67：131-138.
［27］Mateyak MK，Kinzy TG.ADP-ribosylation of translation elongation factor 2 by diphtheria toxin in yeast inhibits translation and cell separation［J］.J Biol Chem，2013，288(34)：24647-24655.
［28］Liu S，Leppla SH.Retroviral insertional mutagenesis identifies a small protein required for synthesis of diphthamide，the target of bacterial ADP-ribosylating toxins［J］.Mol Cell，2003，12(3)：603-613.
［29］Tashiro E，Tsuchiya A，Imoto M.Functions of CyclinD1 as an oncogene and regulation of CyclinD1 expression［J］.Cancer Sci，2007，98(5)：629-635.
［30］Kong F.OVCA1 inhibits the proliferation of epithelial ovarian cancer cells by decreasing CyclinD1 and increasing p16［J］.Mol Cell Biochem，2011，354(1-2)：199-205.
［31］Chen CM，Behringer RR.OVCA1 regulates cell proliferation，embryonic development，and tumorigenesis［J］.Genes Dev，2004，18(3)：320-32.
［32］Chen CM，Behringer RR.OVCA1：tumor suppressor gene［J］.Curr Opin Genet Dev，2005，15(1)：49-54.
［33］Merlo A.5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers［J］.Nat Med，1995，1(7)：686-692.
［34］Pieretti M.Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer［J］.Hum Pathol，1995，26(4)：398-401.
［35］Wales MM.p53 activates expression of HIC-1，a new candidate tumour suppressor gene on 17p13.3［J］.Nat Med，1995，1(6)：570-577.
［36］Stone RM.How I treat patients with myelodysplastic syndromes［J］.Blood，2009，113(25)：6296-6303.
［37］Hu X.Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8［J］.Leuk Res，2013，37(11)：1551-1556.
［38］Wang WY，Cheng WD，Li YH.Expression and significance of the hypermethylated in cancer 1 and ovarian cancer gene 1 in ovarian cancer［J］.China Medical Engineering，2016，4：46-48.［王伟源，程文德，李彦华.癌超甲基化基因1与卵巢癌基因1在卵巢癌组织中的表达及意义［J］.中国医学工程，2016，4：46-48.］
［39］Cornelis RS.Evidence for a gene on 17p13.3，distal to TP53，as a target for allele loss in breast tumors without p53 mutations［J］.Cancer Res，1994，54(15)：4200-4206.
［40］Phelan CM.Consortium study on 1280 breast carcinomas：allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters［J］.Cancer Res，1998，58(5)：1004-1012.
［41］Saxena A.Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas［J］.Cancer Res，1992，52(23)：6716-6721.
［42］Steichen-Gersdorf E.Deletion mapping on chromosome 17p in medulloblastoma［J］.Br J Cancer，1997，76(10)：1284-1287.
［43］Yu JC.Human gastric adenocarcinoma allelotype on chromosomes 17 and 18［J］.J Int Med Res，2008，36(2)：279-288.
［44］Yu J.Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions［J］.Mol Cells，2011，32(1)：47-55.